TYMS and small cell lung carcinoma: Elevated TS and dysregulated pyrimidine metabolism in SCLC may render conventional TS inhibitors relatively ineffective for SCLC treatment; however, a reliance on de novo Thy biosynthesis represents a highly attractive target for new agents with improved capacity for inhibiting elevated TS.